Verition Fund Management’s PTC Therapeutics PTCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.22M Buy
+15,000
New +$1.08M 0.01% 1351
2026
Q1
Sell
-20,200
Closed -$1.53M 3283
2025
Q4
$1.53M Sell
20,200
-16,870
-46% -$1.23M 0.01% 1830
2025
Q3
$2.27M Sell
37,070
-78,338
-68% -$4.08M 0.01% 1864
2025
Q2
$5.64M Buy
115,408
+80,005
+226% +$3.8M 0.03% 986
2025
Q1
$1.8M Sell
35,403
-6,483
-15% -$324K 0.01% 1652
2024
Q4
$1.89M Buy
41,886
+9,152
+28% +$392K 0.01% 1588
2024
Q3
$1.21M Buy
32,734
+1,669
+5% +$55.9K 0.01% 1752
2024
Q2
$950K Buy
31,065
+7,485
+32% +$242K 0.01% 1709
2024
Q1
$686K Sell
23,580
-980
-4% -$27.4K ﹤0.01% 1837
2023
Q4
$677K Sell
24,560
-674
-3% -$15.4K 0.01% 1359
2023
Q3
$565K Sell
25,234
-1,687
-6% -$62.7K 0.01% 1374
2023
Q2
$1.09M Buy
26,921
+3,897
+17% +$191K 0.01% 894
2023
Q1
$1.12M Sell
23,024
-693
-3% -$31.7K 0.02% 904
2022
Q4
$905K Sell
23,717
-1,057
-4% -$43.9K 0.01% 960
2022
Q3
$1.24M Sell
24,774
-2,035
-8% -$99.7K 0.01% 1244
2022
Q2
$1.07M Buy
+26,809
New +$940K 0.02% 979
2021
Q2
Sell
-8,227
Closed -$390K 2082
2021
Q1
$390K Buy
+8,227
New +$489K ﹤0.01% 984
2020
Q1
Sell
-25,274
Closed -$1.21M 962
2019
Q4
$1.21M Buy
+25,274
New +$1.07M 0.02% 392
2019
Q3
Sell
-47,306
Closed -$2.06M 1275
2019
Q2
$2.13M Buy
+47,306
New +$1.87M 0.06% 229
2018
Q2
Sell
-14,006
Closed -$379K 1267
2018
Q1
$379K Buy
+14,006
New +$355K 0.03% 728

Other funds holding PTCT

Verition Fund Management's PTCT Position: Q2 2026 in Review

Verition Fund Management opened a new position in PTC Therapeutics (PTCT) in Q2 2026: 15,000 shares worth $1.22M. The stake represents 0.01% of the portfolio and ranks #1351 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in PTCT as recently as Q4 2025.

Verition Fund Management first reported a position in PTCT in Q1 2018 and has held it in 20 quarters since. The position peaked at $5.64M in Q2 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Verition Fund Management held 15,000 shares of PTC Therapeutics worth $1.22M as of Q2 2026.
  • PTC Therapeutics was a new Verition Fund Management position in Q2 2026.
  • PTC Therapeutics made up 0.01% of Verition Fund Management's portfolio in Q2 2026, its #1351 holding.
  • Verition Fund Management first reported a position in PTC Therapeutics in Q1 2018 and has held it in 20 quarters since.
  • Verition Fund Management's PTC Therapeutics position peaked at $5.64M in Q2 2025.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.